Spyre Therapeutics (SYRE) Cash from Financing Activities (2015 - 2026)

Spyre Therapeutics' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $12.3 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 9704.0% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $321.2 million (up 34.45% YoY) and the FY2025 annual result came in at $309.0 million, down 24.79% from the prior year.
• Cash from Financing Activities was $12.3 million for Q1 2026 at Spyre Therapeutics, down from $312.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $312.8 million in Q4 2025 and bottomed at -$12.5 million in Q3 2023.
• A 5-year average of $66.8 million and a median of $731000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 2045175.0% in 2023, while the deepest fall reached 9539.23% in 2023.
• Spyre Therapeutics' Cash from Financing Activities stood at -$8000.0 in 2022, then surged by 2045175.0% to $163.6 million in 2023, then jumped by 37.89% to $225.6 million in 2024, then soared by 38.66% to $312.8 million in 2025, then sank by 96.08% to $12.3 million in 2026.
• Business Quant data shows SYRE's Cash from Financing Activities at $12.3 million in Q1 2026, $312.8 million in Q4 2025, and -$4.6 million in Q3 2025.